CoChat

The BRCA2 mutation status shapes the immune phenotype of prostate cancer

Open access
Jenzer, Maximilian, Keß, Peter, Nientiedt, Cathleen, Endris, Volker, Kippenberger, Maximilian, Leichsenring, Jonas, Stögbauer, Fabian, Haimes, Josh, Mishkin, Skyler, Kudlow, Brian, Kaczorowski, Adam, Zschäbitz, Stefanie, Volckmar, Anna-Lena, Sültmann, Holger, Jäger, Dirk, Duensing, Anette, Schirmacher, Peter, Hohenfellner, Markus, Grüllich, Carsten, Stenzinger, Albrecht, Duensing, Stefan · 2019 · Cancer Immunology, Immunotherapy
Cited by 53

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Defects in DNA damage repair caused by mutations in BRCA1/2, ATM or other genes have been shown to play an important role in the development and progression of prostate cancer. The influence of such mutations on anti-tumor immunity in prostate cancer, however, is largely unknown. To better understand the correlation between BRCA1/2 mutations and the immune phenotype in prostate cancer, we characterized the immune infiltrate of eight BRCA2-mutated tumors in comparison with eight BRCA1/2 wild-type patients by T-cell receptor sequencing and immunohistochemistry for CD45, CD4, CD8, FOXP3, and CD163. In addition, we analyzed seven prostate cancer biopsies that were either BRCA2 or ATM-mutated in comparison with wild-type tumors. Whereas in BRCA1/2 wild-type tumors, immune cells were found predominantly extratumorally, most BRCA2-mutated tumors including one biopsy showed a significantly increased intratumoral immune cell infiltration. The ratio of intratumoral to extratumoral immune cells was considerably higher in BRCA2-mutated tumors for all markers and reached statistical significance for CD4 (p = 0.007), CD8 (p = 0.006), and FOXP3 (p = 0.001). However, the intratumoral CD8 to FOXP3 ratio showed a trend to be lower in BRCA2-mutated tumors suggesting a more suppressed tumor immune microenvironment. Our findings provide a rationale for the future use of immune oncological approaches in BRCA2-mutated prostate cancer and may encourage efforts to target immunosuppressive T-cell populations to prime tumors for immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00262-019-02393-x

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 53

Metadata

Authors
Jenzer, M., Keß, P., Nientiedt, C., Endris, V., Kippenberger, M., Leichsenring, J., Stögbauer, F., Haimes, J., Mishkin, S., Kudlow, B., Kaczorowski, A., Zschäbitz, S., Volckmar, A.-L., Sültmann, H., Jäger, D., Duensing, A., Schirmacher, P., Hohenfellner, M., Grüllich, C., Stenzinger, A., & Duensing, S.
Venue
Cancer Immunology, Immunotherapy
Published
2019-09-23
Volume
68
Issue
10
Pages
1621-1633
ISSN
  • 0340-7004 (ISSN-L)
  • 1432-0851
OpenAlex
W2975372829
Cited by
53
References
10
FWCI
2.81
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The BRCA2 mutation status shapes the immune phenotype of prostate cancer. https://app.cochat.ai/papers/10.1007/s00262-019-02393-x
The paper
Jenzer, M., Keß, P., Nientiedt, C., Endris, V., Kippenberger, M., Leichsenring, J., Stögbauer, F., Haimes, J., Mishkin, S., Kudlow, B., Kaczorowski, A., Zschäbitz, S., Volckmar, A.-L., Sültmann, H., Jäger, D., Duensing, A., Schirmacher, P., Hohenfellner, M., Grüllich, C., . . . Duensing, S. (2019). The BRCA2 mutation status shapes the immune phenotype of prostate cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-019-02393-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.